Literature DB >> 16968401

Relevance of neutrophils in the murine model of haemolytic uraemic syndrome: mechanisms involved in Shiga toxin type 2-induced neutrophilia.

G C Fernandez1, M F Lopez, S A Gomez, M V Ramos, L V Bentancor, R J Fernandez-Brando, V I Landoni, G I Dran, R Meiss, M A Isturiz, M S Palermo.   

Abstract

It has been demonstrated that infections due to Shiga toxins (Stx) producing Escherichia coli are the main cause of the haemolytic uraemic syndrome (HUS). However, the contribution of the inflammatory response in the pathogenesis of the disease has also been well established. Neutrophils (PMN) represent a central component of inflammation during infections, and patients with high peripheral PMN counts at presentation have a poor prognosis. The mouse model of HUS, by intravenous injection of pure Stx type 2 (Stx2), reproduces human neutrophilia and allows the study of early events in the course of Stx2-induced pathophysiological mechanisms. The aim of this study was to address the contribution of PMN on Stx2 toxicity in a murine model of HUS, by evaluating the survival and renal damage in mice in which the granulocytic population was depleted. We found that the absence of PMN reduced Stx2-induced lethal effects and renal damage. We also investigated the mechanisms underlying Stx2-induced neutrophilia, studying the influence of Stx2 on myelopoyesis, on the emergence of cells from the bone marrow and on the in vivo migration into tissues. Stx2 administration led to an accelerated release of bone marrow cells, which egress at an earlier stage of maturation, together with an increase in the proliferation of myeloid progenitors. Moreover, Stx2-treated mice exhibited a lower migratory capacity to a local inflammatory site. In conclusion, PMN are essential in the pathogenesis of HUS and neutrophilia is not merely an epiphenomenon, but contributes to Stx2-damaging mechanism by potentiating Stx2 toxicity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16968401      PMCID: PMC1809733          DOI: 10.1111/j.1365-2249.2006.03155.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  37 in total

1.  Dynamics of hemopoietic proliferation in man and mice studied by H3-thymidine incorporation into DNA.

Authors:  E P CRONKITE; T M FLIEDNER; V P BOND; J R RUBINI
Journal:  Ann N Y Acad Sci       Date:  1959-06-25       Impact factor: 5.691

Review 2.  Chemoattractant receptor cross-desensitization.

Authors:  H Ali; R M Richardson; B Haribabu; R Snyderman
Journal:  J Biol Chem       Date:  1999-03-05       Impact factor: 5.157

3.  Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9).

Authors:  J F Pruijt; W E Fibbe; L Laterveer; R A Pieters; I J Lindley; L Paemen; S Masure; R Willemze; G Opdenakker
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

4.  Monocyte chemoattractant protein-1 and interleukin-8 levels in urine and serum of patents with hemolytic uremic syndrome.

Authors:  P A van Setten; V W van Hinsbergh; L P van den Heuvel; F Preyers; H B Dijkman; K J Assmann; T J van der Velden; L A Monnens
Journal:  Pediatr Res       Date:  1998-06       Impact factor: 3.756

5.  Prognostic markers in diarrhoea-associated haemolytic-uraemic syndrome: initial neutrophil count, human neutrophil elastase and von Willebrand factor antigen.

Authors:  D V Milford; J Staten; I MacGreggor; J Dawes; C M Taylor; F G Hill
Journal:  Nephrol Dial Transplant       Date:  1991       Impact factor: 5.992

6.  Receptor class desensitization of leukocyte chemoattractant receptors.

Authors:  J R Didsbury; R J Uhing; E Tomhave; C Gerard; N Gerard; R Snyderman
Journal:  Proc Natl Acad Sci U S A       Date:  1991-12-15       Impact factor: 11.205

7.  Neutrophil activation in the haemolytic uraemic syndrome: free and complexed elastase in plasma.

Authors:  M M Fitzpatrick; V Shah; G Filler; M J Dillon; T M Barratt
Journal:  Pediatr Nephrol       Date:  1992-01       Impact factor: 3.714

8.  Interleukin-8 and polymorphoneutrophil leucocyte activation in hemolytic uremic syndrome of childhood.

Authors:  M M Fitzpatrick; V Shah; R S Trompeter; M J Dillon; T M Barratt
Journal:  Kidney Int       Date:  1992-10       Impact factor: 10.612

9.  Identification of a novel granulocyte chemotactic protein (GCP-2) from human tumor cells. In vitro and in vivo comparison with natural forms of GRO, IP-10, and IL-8.

Authors:  P Proost; C De Wolf-Peeters; R Conings; G Opdenakker; A Billiau; J Van Damme
Journal:  J Immunol       Date:  1993-02-01       Impact factor: 5.422

10.  Inhibition of leukocyte emigration induced during the systemic inflammatory reaction in vivo is not due to IL-8.

Authors:  B Schleiffenbaum; J Fehr; B Odermatt; R Sperb
Journal:  J Immunol       Date:  1998-10-01       Impact factor: 5.422

View more
  19 in total

1.  CXCL1/KC and CXCL2/MIP-2 are critical effectors and potential targets for therapy of Escherichia coli O157:H7-associated renal inflammation.

Authors:  James K Roche; Tiffany R Keepers; Lisa K Gross; Regina M Seaner; Tom G Obrig
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

2.  Tolerance to lipopolysaccharide promotes an enhanced neutrophil extracellular traps formation leading to a more efficient bacterial clearance in mice.

Authors:  V I Landoni; P Chiarella; D Martire-Greco; P Schierloh; N van-Rooijen; B Rearte; M S Palermo; M A Isturiz; G C Fernández
Journal:  Clin Exp Immunol       Date:  2012-04       Impact factor: 4.330

Review 3.  Shiga toxin pathogenesis: kidney complications and renal failure.

Authors:  Tom G Obrig; Diana Karpman
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

Review 4.  Practical murine hematopathology: a comparative review and implications for research.

Authors:  Karyn E O'Connell; Amy M Mikkola; Aaron M Stepanek; Andyna Vernet; Christopher D Hall; Chia C Sun; Eda Yildirim; John F Staropoli; Jeannie T Lee; Diane E Brown
Journal:  Comp Med       Date:  2015-04       Impact factor: 0.982

5.  Induction of Neutrophil Extracellular Traps in Shiga Toxin-Associated Hemolytic Uremic Syndrome.

Authors:  Maria Victoria Ramos; Maria Pilar Mejias; Florencia Sabbione; Romina Jimena Fernandez-Brando; Adriana Patricia Santiago; Maria Marta Amaral; Ramon Exeni; Analia Silvina Trevani; Marina Sandra Palermo
Journal:  J Innate Immun       Date:  2016-05-28       Impact factor: 7.349

6.  Comparative analysis of the abilities of Shiga toxins 1 and 2 to bind to and influence neutrophil apoptosis.

Authors:  Michael J Flagler; Jane E Strasser; Claudia L Chalk; Alison A Weiss
Journal:  Infect Immun       Date:  2006-11-13       Impact factor: 3.441

Review 7.  Pathogenic role of inflammatory response during Shiga toxin-associated hemolytic uremic syndrome (HUS).

Authors:  Ramon Alfonso Exeni; Romina Jimena Fernandez-Brando; Adriana Patricia Santiago; Gabriela Alejandra Fiorentino; Andrea Mariana Exeni; Maria Victoria Ramos; Marina Sandra Palermo
Journal:  Pediatr Nephrol       Date:  2018-01-25       Impact factor: 3.714

8.  Pathogenesis of renal disease due to enterohemorrhagic Escherichia coli in germ-free mice.

Authors:  Kathryn A Eaton; David I Friedman; Gayle J Francis; Jessica S Tyler; Vincent B Young; Jennifer Haeger; Galeb Abu-Ali; Thomas S Whittam
Journal:  Infect Immun       Date:  2008-04-28       Impact factor: 3.441

9.  Renal damage and death in weaned mice after oral infection with Shiga toxin 2-producing Escherichia coli strains.

Authors:  R J F Brando; E Miliwebsky; L Bentancor; N Deza; A Baschkier; M V Ramos; G C Fernández; R Meiss; M Rivas; M S Palermo
Journal:  Clin Exp Immunol       Date:  2008-06-28       Impact factor: 4.330

10.  Retinoid levels influence enterohemorrhagic Escherichia coli infection and Shiga toxin 2 susceptibility in mice.

Authors:  Gabriel Cabrera; Romina J Fernández-Brando; María Jimena Abrey-Recalde; Ariela Baschkier; Alipio Pinto; Jorge Goldstein; Elsa Zotta; Roberto Meiss; Marta Rivas; Marina S Palermo
Journal:  Infect Immun       Date:  2014-07-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.